BY ANJA HAUGE
-
Novartis challenges US price negotiations in the Supreme Court
Besides Novartis, business consisting of AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novo Nordisk, and Boehringer Ingelheim have actually likewise taken the instance…
-
Bavarian Nordic faces skepticism in France after Valneva’s chikungunya challenges
Nevertheless, Bavarian Nordic has actually not seen any kind of unfavorable influence in spite of significant obstacles dealt with by its rival Valneva.
-
Roche trial shows significant weight loss with drug candidate
Majority of the individuals in a test shed greater than 20% of their body weight after 48 weeks on the medication prospect CT-388.
-
Big Latin American sale to ensure Bavarian Nordic cheaper production of chikungunya vaccine
At First, Bavarian Nordic will certainly not gain substantial profits from marketing the vaccination in Brazil. Nonetheless, the development right into Latin America provides the f…
-
Two top executives leave in quick succession – Evaxion’s new CEO sees no red flags
Helen Tayton-Martin did not offer much idea to the previous Chief executive officers when she approved the task as Evaxion’s brand-new magnate. Nevertheless, her objectives a…
-
ALK executives fear no direct competition after GSK acquisition: “But we must remain vigilant”
Rather, GSK and ALK might wind up with corresponding therapies.
-
Bavarian Nordic sharpens focus after competitor’s chikungunya exit
Since France’s Valneva has actually left the chikungunya market in the United States, Bavarian Nordic states the Danish firm has a higher duty to elevate recognition of and a…
-
Competition intensifies in the peanut allergy market – analysts see opportunity for ALK
With a solid American concentrate on peanut allergic reactions, ALK might accomplish its long-awaited innovation in the United States if the firm’s injection prospect verifie…
-
Two top executives leave in quick succession – Evaxion’s new CEO sees no red flags
Helen Tayton-Martin did not offer much idea to the previous Chief executive officers when she approved the task as Evaxion’s brand-new magnate. Nevertheless, her objectives a…
-
Novo Nordisk challenges Eli Lilly’s claims about new weight-loss pill
Danish drugmaker takes an uncommonly straight strategy in slamming its rival’s cases concerning the effectiveness, adverse effects and use weight-loss tablet computers.
